Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead and Merck announced that the primary efficacy endpoint was met in both Phase 3 ISLEND-1 and ISLEND-2 trials for the investigational once-weekly oral HIV regimen of islatravir/lenacapavir. The combination was found to be statistically non-inferior to BIKTARVY in ISLEND-1 and to standard of care daily oral antiretroviral therapy in ISLEND-2, with a comparable safety profile.
Key figures
- Drug Name
- Islatravir/Lenacapavir
- Phase Of Trial
- Phase 3
- Trial names
- ["ISLEND-1","ISLEND-2"]
- Islatravir dose
- 2 mg
- Dosing frequency
- once-weekly
- Lenacapavir dose
- 300 mg
- Primary endpoint met
- Yes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.